The only bispecific T-cell engagers currently approved for solid tumors are tebentafusp (CD3 x gp100) for uveal melanoma15 and tarlatamab (CD3 x DLL3) for small cell lung cancer.16 Hence, data regarding potential mechanisms of resistance in solid tumors are not readily available. This evidence concerns the gene PMEL and small cell lung carcinoma.